An Xuedong, Duan Liyun, Zhang Yue Hong, Jin De, Zhao Shenghui, Zhou Rong Rong, Duan Yingying, Lian Fengmei, Tong Xiaolin
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Chin Med. 2021 Jun 7;16(1):44. doi: 10.1186/s13020-021-00454-x.
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first broke out in Wuhan, China, in 2019. SARS-CoV-2 develops many types of mutations (such as B.1.1.7), making diagnosis and treatment challenging. Although we now have a preliminary understanding of COVID-19, including pathological changes, clinical manifestations, and treatment measures, we also face new difficulties. The biggest problem is that most COVID-19 patients might face sequelae (e.g., fatigue, sleep disturbance, pulmonary fibrosis) during the recovery phase. We aimed to test six Chinese patent medicines to treat three major abnormal symptoms in COVID-19 patients during the recovery phase, including cardiopulmonary function, sleep disturbance, and digestive function. We launched the "three syndromes and six Chinese patent medicines" randomized, double-blind, placebo-controlled, multicenter clinical trial on April 10, 2020. The results showed that Jinshuibao tablets and Shengmaiyin oral liquid significantly improved the cardiopulmonary function of recovering COVID-19 patients. Shumian capsules, but not Xiaoyao capsules, significantly improved patients' sleep disorders. This might be because the indication of Xiaoyao capsules is liver qi stagnation rather than psychological or emotional problems. Xiangsha Liujun pills and Ludangshen oral liquid significantly improved digestive function. Our research provides a guideline for treating COVID-19 sequelae in patients during the recovery period based on high-quality evidence.
2019年冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，于2019年在中国武汉首次爆发。SARS-CoV-2发生了多种类型的突变（如B.1.1.7），这使得诊断和治疗具有挑战性。尽管我们现在对COVID-19已经有了初步了解，包括病理变化、临床表现和治疗措施，但我们也面临着新的困难。最大的问题是，大多数COVID-19患者在康复阶段可能会面临后遗症（如疲劳、睡眠障碍、肺纤维化）。我们旨在测试六种中成药，以治疗COVID-19患者康复阶段的三大异常症状，包括心肺功能、睡眠障碍和消化功能。我们于2020年4月10日启动了“三证六药”随机、双盲、安慰剂对照、多中心临床试验。结果显示，金水宝片和生脉饮口服液显著改善了康复期COVID-19患者的心肺功能。舒眠胶囊而非逍遥胶囊显著改善了患者的睡眠障碍。这可能是因为逍遥胶囊的适应症是肝气郁结而非心理或情绪问题。香砂六君丸和潞党参口服液显著改善了消化功能。我们的研究基于高质量证据为治疗COVID-19康复期患者的后遗症提供了指导。
